Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling ¬of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial.
228 circulat...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 1.4MB)
- Publisher copy:
- Copyright holder:
- Copyright date:
- © 2018 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record